Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 6 , Pages 406-411 , June 2011

ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk

Received 20 April 2009 ,Revised 10 September 2009 ,Accepted 2 November 2009.

References 

  1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. J Am Med Assoc. 1987;257:2176–2180
  2. Genest J, McNamara JR, Ordovas JM, Silberman SR, Anderson KM, Wilson PW, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792–802
  3. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033
  4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255:188–205
  5. Yusuf S, Hawken S, Öunpuu S, Dans T, Avezum A, Fernando L, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952
  6. Meisenger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J. 2005;26:271–278
  7. Sniderman AD, Furberg CD, Keech A, Roeter s van Lennep JE, Frohlic J, Junger I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777–780
  8. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy- a review of the evidence. J Intern Med. 2006;259:493–519
  9. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  11. Expert Panel on Detection . Evaluation, and treatment of high blood cholesterol in adults, third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult treatment Panel III) final report. Circulation. 2002;106:3143–3421
  12. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
  13. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Morton Hawkins F, et al. Effect of Pravastatin on coronary disease in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–1900
  14. Pyörälä K, Ballanttyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Survival Study (4S). Diabetes Care. 2004;27:1735–1740
  15. Grundy SM, Hansen B, Smith SC, Cleeman JI, Khan RA for Conference Participants. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association on scientific issues related to management. Circulation. 2004;4:551–556
  16. Expert Committee on the diagnosis and classification of diabetes mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:S5–20
  17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care. 2004;27:1487–1495
  18. Levenson JW, Skerret PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol. 2002;5:88–89
  19. Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherogenesis in asymptomatic men. Atherosclerosis. 2005;179:339–344
  20. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyörälä K. DECODE Study, Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;10:1066–1076
  21. Marcovina S, Packard CJ. Measurements and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med. 2006;259:437–446
  22. Sniderman AD. Apolipoprotein B versus no-high density lipoprotein cholesterol. And the winner is …. Circulation. 2005;112:336–337
  23. Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. Eur Heart J Suppl. 2005;7:F4–8
  24. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. J Am Med Assoc. 2007;298:776–785
  25. Shai I, Rimm EB, Hankinson SE, Curhan E, Manson JE, Rifai N, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation. 2004;110:2824–2830
  26. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med. 2001;39:426–431
  27. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem. 2003;36:499–504
  28. Steinmetz J, Caces E, Couderc R, Beucler I, Legrand A, Henney J. Reference values of apolipoproteins AI and B. Contribution of International standardization. Ann Biol Clin. 1997;55:451–454
  29. Denke MA. Weighing in before the fight. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation. 2005;112:3368–3370

PII: S0939-4753(09)00280-4

doi: 10.1016/j.numecd.2009.11.002

Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 6 , Pages 406-411 , June 2011

Article Tools